SCHEMBL10213533

SCHEMBL10213533

c1ccc2sc(-c3cc(-c4ccc5[nH]ncc5c4)cc4cn[nH]c34)cc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 13/20 0.60
GSK3B P49841 4/20 0.52
CDK5 Q00535 4/20 0.52
DYRK1A Q13627 4/20 0.52
PLK4 O00444 3/20 0.52
MAPK13 O15264 3/20 0.52
PDPK1 O15530 3/20 0.52
DAPK3 O43293 3/20 0.52
ROCK2 O75116 3/20 0.52
CHEK2 O96017 3/20 0.52
PRKCG P05129 3/20 0.52
CDK1 P06493 3/20 0.52
PRKACA P17612 3/20 0.52
CDK2 P24941 3/20 0.52
MARK3 P27448 3/20 0.52
AKT2 P31751 3/20 0.52
FLT4 P35916 3/20 0.52
CSNK1D P48730 3/20 0.52
GSK3A P49840 3/20 0.52
RPS6KA3 P51812 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10269404 0.86 MAPKAPK2 (0.60) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL13201333 0.85 GSK3B (0.58) MAPKAPK2GSK3BCDK5DYRK1AMAPK13
SCHEMBL10213517 0.83 MAPKAPK2 (0.60) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL10269156 0.83 MAPKAPK2 (0.57) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL10213534 0.83 MAPKAPK2 (0.55) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL760551 0.82 MAPKAPK2 (0.71) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL10213393 0.82 MAPKAPK2 (0.56) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL758279 0.81 MAPKAPK2 (0.53) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL759934 0.81 MAPKAPK2 (0.53) MAPKAPK2GSK3BCDK5DYRK1APLK4
SCHEMBL10213473 0.81 MAPKAPK2 (0.57) MAPKAPK2GSK3BCDK5DYRK1APLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
WO-2007117465-A2 INDAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 MAPKAPK2 1905/4885GSK3B 1016/4885CDK5 1473/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 MAPKAPK2 1905/4885GSK3B 1016/4885CDK5 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.